Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Captrust Financial Advisors

Captrust Financial Advisors raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 108.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,689 shares of the medical research company’s stock after acquiring an additional 2,963 shares during the quarter. Captrust Financial Advisors’ holdings in Natera were worth $722,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the 2nd quarter worth approximately $28,000. Quarry LP increased its position in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares in the last quarter. Covestor Ltd increased its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new stake in shares of Natera in the third quarter valued at $70,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the sale, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. This trade represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 1,196 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the transaction, the insider now owns 110,695 shares of the company’s stock, valued at $13,085,255.95. This trade represents a 1.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 133,976 shares of company stock valued at $21,119,238 over the last three months. 7.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently commented on NTRA. Leerink Partners lifted their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group raised their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. TD Cowen boosted their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird increased their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $140.59.

Natera Stock Down 0.8 %

Shares of NASDAQ:NTRA opened at $166.45 on Wednesday. Natera, Inc. has a 1 year low of $55.56 and a 1 year high of $175.63. The stock has a 50-day simple moving average of $141.76 and a 200-day simple moving average of $123.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market capitalization of $21.97 billion, a P/E ratio of -94.57 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the previous year, the firm earned ($0.95) earnings per share. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. Equities analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.